Principal component analysis of the effects of environmental enrichment and (-)-epigallocatechin-3-gallate on age-associated learning deficits in a mouse model of down syndrome

Frontiers in Behavioral Neuroscience

Volumn 9, Issue DEC, 2015, Pages

  Catuara Solarz, Silvina ^a,b   Espinosa Carrasco, Jose ^a,b   Erb, Ionas ^a,b   Langohr, Klaus ^c,d   Notredame, Cedric ^a,b   Gonzalez, Juan R ^a,e,f   Dierssen, Mara ^a,b,g  

^a BARCELONA INSTITUTE OF SCIENCE AND TECHNOLOGY   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^e CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^f CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^g CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

( ) epigallocatechin 3 gallate; Aging; Down syndrome; Morris water maze; Principal component analysis

Indexed keywords

EPIGALLOCATECHIN GALLATE;

ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; COGNITIVE FLEXIBILITY; CONTROLLED STUDY; DOWN SYNDROME; DRUG EFFICACY; ENVIRONMENTAL ENRICHMENT; FEMALE; GENOTYPE; MALE; MOUSE; NONHUMAN; PRINCIPAL COMPONENT ANALYSIS; REFERENCE MEMORY; SPATIAL LEARNING;

EID: 84957598115     PISSN: 16625153     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnbeh.2015.00330     Document Type: Article

References (62)

1. Adayev, T., Murakami, N., Wegiel, J., and Hwang, Y. (2006). Kinetic properties of a MNB/DYRK1A mutant suitable for the elucidation of biochemical pathways. Biochemistry 45, 12011–12019. doi:10.1021/bi060632j.
2. Baamonde, C., Martínez-Cué, C., Flórez, J., and Dierssen, M. (2011). G-protein-associated signal transduction processes are restored after postweaning environmental enrichment in Ts65Dn, a Down syndrome mouse model. Dev. Neurosci. 33, 442–450. doi:10.1159/000329425.
3. Bain, J., McLauchlan, H., Elliott, M., and Cohen, P. (2003). The specificities of protein kinase inhibitors: an update. Biochem. J. 371(Pt 1), 199–204. doi:10.1042/BJ20021535.
4. Becker, W., Soppa, U., and Tejedor, F. J. (2014). DYRK1A: a potential drug target for multiple Down syndrome neuropathologies. CNS Neurol. Disord. Drug Targets 13, 26–33. doi:10.2174/18715273113126660186.
5. Begenisic, T., Spolidoro, M., Braschi, C., Baroncelli, L., Milanese, M., Pietra, G., et al. (2011). Environmental enrichment decreases GABAergic inhibition and improves cognitive abilities, synaptic plasticity, and visual functions in a mouse model of Down syndrome. Front. Cell. Neurosci. 5:29. doi:10.3389/fncel.2011.00029.
6. Benjamini, Y., and Hochberg, Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 57, 289–300.
7. Berardi, N., Braschi, C., Capsoni, S., Cattaneo, A., and Maffei, L. (2007). Environmental enrichment delays the onset of memory deficits and reduces neuropathological hallmarks in a mouse model of Alzheimer-like neurodegeneration. J. Alzheimers Dis. 11, 359–370.
8. Biasibetti, R., Tramontina, A. C., Costa, A. P., Dutra, M. F., Quincozes-Santos, A., Nardin, P., et al. (2013). Green tea (-)epigallocatechin-3-gallate reverses oxidative stress and reduces acetylcholinesterase activity in a streptozotocin-induced model of dementia. Behav. Brain Res. 236, 186–193. doi:10.1016/j.bbr.2012.08.039.
9. Birch, A. M., McGarry, N. B., and Kelly, A. M. (2013). Short-term environmental enrichment, in the absence of exercise, improves memory, and increases NGF concentration, early neuronal survival, and synaptogenesis in the dentate gyrus in a time-dependent manner. Hippocampus 23, 437–450. doi:10.1002/hipo.22103.
10. Cataldo, A. M., Petanceska, S., Peterhoff, C. M., Terio, N. B., Epstein, C. J., Villar, A., et al. (2003). App gene dosage modulates endosomal abnormalities of Alzheimer’s disease in a segmental trisomy 16 mouse model of Down syndrome. J. Neurosci. 23, 6788–6792.
11. Chakrabarti, L., Scafidi, J., Gallo, V., and Haydar, T. F. (2011). Environmental enrichment rescues postnatal neurogenesis defect in the male and female Ts65Dn mouse model of Down syndrome. Dev. Neurosci. 33, 428–441. doi:10.1159/000329423.
12. Contestabile, A., Fila, T., Bartesaghi, R., Contestabile, A., and Ciani, E. (2006). Choline acetyltransferase activity at different ages in brain of Ts65Dn mice, an animal model for Down’s syndrome and related neurodegenerative diseases. J. Neurochem. 97, 515–526. doi:10.1111/j.1471-4159.2006.03769.x.
13. De Bruin, J. P., Sànchez-Santed, F., Heinsbroek, R. P., Donker, A., and Postmes, P. (1994). A behavioural analysis of rats with damage to the medial prefrontal cortex using the Morris water maze: evidence for behavioural flexibility, but not for impaired spatial navigation. Brain Res. 652, 323–333. doi:10.1016/0006-8993(94)90243-7.
14. De la Torre, R., De Sola, S., Pons, M., Duchon, A., de Lagran, M. M., Farré, M., et al. (2014). Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans. Mol. Nutr. Food Res. 58, 278–288. doi:10.1002/mnfr.201300325.
15. De la Torre, R., and Dierssen, M. (2012). Therapeutic Approaches in the Improvement of Cognitive Performance in Down Syndrome: Past, Present, and Future. New York, NY: Elsevier Inc.
16. Dickhaus, T. (2012). Multiple Comparisons Using R by BRETZ, F., HOTHORN, T., and WESTFALL, P. Biometrics 68, 995–995. doi:10.1111/j.1541-0420.2012.01813.x.
17. Dierssen, M. (2012). Down syndrome: the brain in trisomic mode. Nat. Rev. Neurosci. 13, 844–858. doi:10.1038/nrn3314.
18. Dierssen, M., Benavides-Piccione, R., Martínez-Cué, C., Estivill, X., Flórez, J., Elston, G. N., et al. (2003). Alterations of neocortical pyramidal cell phenotype in the Ts65Dn mouse model of Down syndrome: effects of environmental enrichment. Cereb. Cortex 13, 758–764.
19. Gallagher, M., Burwell, R., and Burchinal, M. R. (1993). Severity of spatial learning impairment in aging: development of a learning index for performance in the Morris water maze. Behav. Neurosci. 107, 618–626. doi:10.1037/0735-7044.107.4.618.
20. Golabek, A., Jarz, K., Palminiello, S., Walus, M., Rabe, A., and Albertini, G. (2011). “Brain plasticity and environmental enrichment in Ts65Dn mice, an animal model for Down syndrome,” in Neurocognitive Rehabilitation of Down Syndrome (New York, NY: Cambridge University Press), 71–84.
21. Granholm, A. C., Sanders, L. A., and Crnic, L. S. (2000). Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down’s syndrome. Exp. Neurol. 161, 647–663. doi:10.1006/exnr.1999.7289.
22. Graziano, A., Petrosini, L., and Bartoletti, A. (2003). Automatic recognition of explorative strategies in the Morris water maze. J. Neurosci. Methods 130, 33–44. doi:10.1016/S0165-0270(03)00187-0.
23. Greenacre, M. J. (2010). Biplots in Practice. Bilbao: Fundacion BBVA.
24. Gundimeda, U., McNeill, T. H., Fan, T. K., Deng, R., Rayudu, D., Chen, Z., et al. (2014). Green tea catechins potentiate the neuritogenic action of brain-derived neurotrophic factor: role of 67-kDa laminin receptor and hydrogen peroxide. Biochem. Biophys. Res. Commun. 445, 218–224. doi:10.1016/j.bbrc.2014.01.166.
25. Hand, D. J., and Taylor, C. C. (1987). Multivariate Analysis of Variance and Repeated Measures: A Practical Approach for Behavioural Scientists. London: CRC Press. Available online at: https://books.google.com/books?id=If5OXdzHFScC&pgis=1 (Accessed July 29, 2015).
26. Henningsen, A. (2013). censReg: Censored Regression (Tobit) Models. R Package Version 0.5-20. Available online at: http://CRAN.R-project.org/package=censReg.
27. Hof, P. R. (1995). Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down’s syndrome. Arch. Neurol. 52, 379. doi:10.1001/archneur.1995.00540280065020.
28. Holtzman, D. M., Santucci, D., Kilbridge, J., Chua-Couzens, J., Fontana, D. J., Daniels, S. E., et al. (1996). Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 93, 13333–13338. doi:10.1073/pnas.93.23.13333.
29. Hyman, B. T. (1995). Neuropathological changes in Down’s syndrome hippocampal formation. Arch. Neurol. 52, 373. doi:10.1001/archneur.1995.00540280059019.
30. Ickes, B. R., Pham, T. M., Sanders, L. A., Albeck, D. S., Mohammed, A. H., and Granholm, A. C. (2000). Long-term environmental enrichment leads to regional increases in neurotrophin levels in rat brain. Exp. Neurol. 164, 45–52. doi:10.1006/exnr.2000.7415.
31. Jankowsky, J. L., Melnikova, T., Fadale, D. J., Xu, G. M., Slunt, H. H., Gonzales, V., et al. (2005). Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer’s disease. J. Neurosci. 25, 5217–5224. doi:10.1523/JNEUROSCI.5080-04.2005.
32. Kalfon, L., Youdim, M. B. H., and Mandel, S. A. (2007). Green tea polyphenol (-)-epigallocatechin-3-gallate promotes the rapid protein kinase C-and proteasome-mediated degradation of Bad: implications for neuroprotection. J. Neurochem. 100, 992–1002. doi:10.1111/j.1471-4159.2006.04265.x.
33. Keeley, R. J., and McDonald, R. J. (2015). Part III: principal component analysis: bridging the gap between strain, sex and drug effects. Behav. Brain Res. 288, 153–161. doi:10.1016/j.bbr.2015.03.027.
34. Kim, H.-S., Quon, M. J., and Kim, J.-A. (2014). New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate. Redox Biol. 2, 187–195. doi:10.1016/j.redox.2013.12.022.
35. Lazarov, O., Robinson, J., Tang, Y.-P., Hairston, I. S., Korade-Mirnics, Z., Lee, V. M.-Y., et al. (2005). Environmental enrichment reduces Aβ levels and amyloid deposition in transgenic mice. Cell 120, 701–713. doi:10.1016/j.cell.2005.01.015.
36. Lê, S., Josse, J., and Husson, F. (2008). FactoMineR: an R package for multivariate analysis. J. Stat. Softw. 25, 1–18. doi:10.18637/jss.v025.i01.
37. Lee, Y.-J., Choi, D.-Y., Yun, Y.-P., Han, S. B., Oh, K.-W., and Hong, J. T. (2013). Epigallocatechin-3-gallate prevents systemic inflammation-induced memory deficiency and amyloidogenesis via its anti-neuroinflammatory properties. J. Nutr. Biochem. 24, 298–310. doi:10.1016/j.jnutbio.2012.06.011.
38. Lemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., and Selkoe, D. J. (1996). Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol. Dis. 3, 16–32. doi:10.1006/nbdi.1996.0003.
39. Li, S., Jin, M., Zhang, D., Yang, T., Koeglsperger, T., Fu, H., et al. (2013). Environmental novelty activates β2-adrenergic signaling to prevent the impairment of hippocampal LTP by Aβ oligomers. Neuron 77, 929–941. doi:10.1016/j.neuron.2012.12.040.
40. Lott, I. T., and Dierssen, M. (2010). Cognitive deficits and associated neurological complications in individuals with Down’s syndrome. Lancet Neurol. 9, 623–633. doi:10.1016/S1474-4422(10)70112-5.
41. Mann, D. M. A. (1988). The pathological association between down syndrome and Alzheimer disease. Mech. Ageing Dev. 43, 99–136. doi:10.1016/0047-6374(88)90041-3.
42. Mármol, F., Rodríguez, C. A., Sánchez, J., and Chamizo, V. D. (2015). Anti-oxidative effects produced by environmental enrichment in the hippocampus and cerebral cortex of male and female rats. Brain Res. 1613, 120–129. doi:10.1016/j.brainres.2015.04.007.
43. Martínez-Cué, C., Baamonde, C., Lumbreras, M., Paz, J., Davisson, M. T., Schmidt, C., et al. (2002). Differential effects of environmental enrichment on behavior and learning of male and female Ts65Dn mice, a model for Down syndrome. Behav. Brain Res. 134, 185–200. doi:10.1016/S0166-4328(02)00026-8.
44. Martínez-Cué, C., Rueda, N., García, E., Davisson, M. T., Schmidt, C., and Flórez, J. (2005). Behavioral, cognitive and biochemical responses to different environmental conditions in male Ts65Dn mice, a model of Down syndrome. Behav. Brain Res. 163, 174–185. doi:10.1016/j.bbr.2005.04.016.
45. Obregon, D. F., Rezai-Zadeh, K., Bai, Y., Sun, N., Hou, H., Ehrhart, J., et al. (2006). ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein. J. Biol. Chem. 281, 16419–16427. doi:10.1074/jbc.M600617200.
46. Pollard, K. S., Dudoit, S., and van der Laan, M. J. (2005). “Multiple testing procedures: the multtest package and applications to genomics,” in Bioinformatics and Computational Biology Solutions Using R and Bioconductor (New York, NY: Springer), 249–271. doi: 10.1007/0-387-29362-0_15.
47. Polito, L., Chierchia, A., Tunesi, M., Bouybayoune, I., Kehoe, P. G., Albani, D., et al. (2014). Environmental enrichment lessens cognitive decline in APP23 mice without affecting brain sirtuin expression. J. Alzheimers Dis. 42, 851–864. doi:10.3233/JAD-131430.
48. Pons-Espinal, M., Martinez de Lagran, M., and Dierssen, M. (2013). Environmental enrichment rescues DYRK1A activity and hippocampal adult neurogenesis in TgDyrk1A. Neurobiol. Dis. 60, 18–31. doi:10.1016/j.nbd.2013.08.008.
49. Reeves, R. H., Irving, N. G., Moran, T. H., Wohn, A., Kitt, C., Sisodia, S. S., et al. (1995). A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat. Genet. 11, 177–184. doi:10.1038/ng1095-177.
50. Rezai-Zadeh, K., Arendash, G. W., Hou, H., Fernandez, F., Jensen, M., Runfeldt, M., et al. (2008). Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res. 1214, 177–187. doi:10.1016/j.brainres.2008.02.107.
51. Salehi, A., Delcroix, J.-D., Belichenko, P. V., Zhan, K., Wu, C., Valletta, J. S., et al. (2006). Increased App expression in a mouse model of Down’s syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 51, 29–42. doi:10.1016/j.neuron.2006.05.022.
52. Seo, H., and Isacson, O. (2005). Abnormal APP, cholinergic and cognitive function in Ts65Dn Down’s model mice. Exp. Neurol. 193, 469–480. doi:10.1016/j.expneurol.2004.11.017.
53. Sham, P. C., and Purcell, S. M. (2014). Statistical power and significance testing in large-scale genetic studies. Nat. Rev. Genet. 15, 335–346. doi:10.1038/nrg3706.
54. Vock, D. M., Davidian, M., Tsiatis, A. A., and Muir, A. J. (2012). Mixed model analysis of censored longitudinal data with flexible random-effects density. Biostatistics 13, 61–73. doi:10.1093/biostatistics/kxr026.
55. Vorhees, C. V., and Williams, M. T. (2006). Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat. Protoc. 1, 848–858. doi:10.1038/nprot.2006.116.
56. Wang, D., Wang, F., Tan, Y., Dong, L., Chen, L., Zhu, W., et al. (2012). Discovery of potent small molecule inhibitors of DYRK1A by structure-based virtual screening and bioassay. Bioorg. Med. Chem. Lett. 22, 168–171. doi:10.1016/j.bmcl.2011.11.043.
57. Whishaw, I. Q., and Jarrard, L. E. (1996). Evidence for extrahippocampal involvement in place learning and hippocampal involvement in path integration. Hippocampus 6, 513–524.
58. Wickham, H. (2009). ggplot2: Elegant Graphics for Data Analysis. New York, NY: Springer Science & Business Media. doi:10.1007/978-0-387-98141-3.
59. Wilcock, D. M., and Griffin, W. S. T. (2013). Down’s syndrome, neuroinflammation, and Alzheimer neuropathogenesis. J. Neuroinflammation 10, 84. doi:10.1186/1742-2094-10-84.
60. Wisniewski, K. E., Wisniewski, H. M., and Wen, G. Y. (1985). Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome. Ann. Neurol. 17, 278–282. doi:10.1002/ana.410170310.
61. Wolfer, D. P., and Lipp, H.-P. (2000). Dissecting the behaviour of transgenic mice: is it the mutation, the genetic background, or the environment? Exp. Physiol.85, 627–634. doi:10.1111/j.1469-445x.2000.02095.x.
62. Xicota, L., Rodríguez-Morató, J., Dierssen, M., and de la Torre, R. (2015). Potential role of (-)-epigallocatechin-3-gallate (EGCG) in the secondary prevention of Alzheimer disease. Curr. Drug Targets. doi:10.2174/1389450116666150825113655. [Epubaheadofprint].